^
    Back
    Association details:
    Biomarker:ALK rearrangement
    Cancer:Non Small Cell Lung Cancer
    Drug:Imfinzi (durvalumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

    Excerpt:
    ...Compare Disease free survival (DFS) for patients with NSCLC that is PD-L1 expression TC ≥ 25% and patients without common activating EGFR mutations or ALK gene rearrangements...
    Trial ID:
    ADJUVANT BR.31
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Phase II trial evaluating the efficacy of durvalumab (MEDI4736) as second-line therapy in Non- Small-Cell Lung Cancer patients receiving concomitant steroids Studio di fase II volto a valutare l’efficacia del Durvalumab nei pazienti con tumore al polmone non a piccole cellule che assumano contemporaneamente steroidi

    Excerpt:
    ...Histological or cytological confirmed diagnosis of advanced or metastatic NSCLC with no evidence of EGFR mutations or ALK rearrangement.4. ...
    Trial ID:
    2018-003645-41
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

    Excerpt:
    ...ALK fusion, ROS1 rearrangements, RET fusions, or MET exon 14 skipping mutations where there are standard of care therapy options available....
    Trial ID:
    ENDURE
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer

    Excerpt:
    ...- Absence of EGFR mutation or ALK rearrangement prior to screening...
    Trial ID:
    SCope-D1
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

    Excerpt:
    ...Must NOT be known positive for EGFR TKI sensitizing mutation (Exon 19 deletion or L858R mutation), or ALK/ ROS1 rearrangement....
    Trial ID:
    ADAPT-E
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    1st Line Durvalumab in PS 2 NSCLC Patients

    Excerpt:
    ...ALK fusion oncogene or rearrangements of the ROS1 gene detected in patients with a non-squamous cell NSCLC...
    Trial ID:
    SAKK 19/17
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC

    Excerpt:
    ...ALK or ROS1 gene rearrangements, BRAF V600E mutation, or NTRK gene fusions....
    Trial ID:
    NCT04786093
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Eur J Cancer
    Title:

    Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations

    Published date:
    03/17/2022
    Excerpt:
    In the whole cohort, the median PFS was 17.5 months (mo.) (95% CI, 13.2-24.9) and median OS 47 mo (95%CI, 47-not reached [NR])...when analysed separately: the median PFS was NR (11.3-NR) in the KRASm G12C vs. 8.1 mo (5.8-NR) in the EGFRm del19/ex21 vs. 7.8 mo (7.7-NR) in the BRAFm V600E/ALKr (P = 0.02)....We observed limited activity of durvalumab consolidation in patients with stage III unresectable NSCLC with EGFR/BRAFm and ALKr but not for those harbouring KRASm.
    DOI:
    10.1016/j.ejca.2022.02.014